Perifosine (KRX-0401)

Name: Perifosine (KRX-0401)
Brand: Selleck Chemicals
SKU: S1037
Rating: 5 (155 reviews)

For research use only.

Catalog No.S1037 Synonyms: NSC639966, D21266

155 publications

Perifosine (KRX-0401) Chemical Structure

CAS No. 157716-52-4

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Selleck's Perifosine (KRX-0401) has been cited by 155 publications

Cancer Cell, 2013, 23(6):839-52

PubMed: 23684459 ( click the link to review the publication )

Cell, 2012, 149(3):656-70

PubMed: 22920938 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

IUBMB Life, 2021, 10.1002/iub.2514

PubMed: 34110086 ( click the link to review the publication )

Oncol Rep, 2021, 46(3)202

PubMed: 34296295 ( click the link to review the publication )

Eur J Pharmacol, 2021, 898:173957

PubMed: 33662352 ( click the link to review the publication )

Cardiovasc Toxicol, 2021, 21(8):655-668

PubMed: 34021461 ( click the link to review the publication )

Aging (Albany NY), 2020, 18;12(10):9489-9499

PubMed: 32421688 ( click the link to review the publication )

Front Oncol, 2020, 10:584505

PubMed: 33425737 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa159

PubMed: 33078829 ( click the link to review the publication )

Front Microbiol, 2020, 11:565590

PubMed: 33042070 ( click the link to review the publication )

Cancer Cell Int, 2020, 25;20:134

PubMed: 32351328 ( click the link to review the publication )

J Cell Biochem, 2020, 121(1):723-734

PubMed: 31452248 ( click the link to review the publication )

Transl Oncol, 2020, 13(2):355-364

PubMed: 31887630 ( click the link to review the publication )

Cell Stress Chaperones, 2020, 9

PubMed: 32519137 ( click the link to review the publication )

Biosci Rep, 2020, BSR20201539

PubMed: 33269380 ( click the link to review the publication )

Commun Biol, 2020, 3(1):378

PubMed: 32665601 ( click the link to review the publication )

Sci Rep, 2020, 10(1):10315

PubMed: 32587277 ( click the link to review the publication )

Chin J Integr Med, 2020, 10.1007

PubMed: 31903532 ( click the link to review the publication )

Dev Cell, 2019, 51(2):236-254

PubMed: 31543445 ( click the link to review the publication )

Dev Cell, 2019, 50(2):229-246

PubMed: 31204173 ( click the link to review the publication )

Cancer Lett, 2019, 447:93-104

PubMed: 30660646 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5334

PubMed: 31397884 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627436 ( click the link to review the publication )
Cancers (Basel), 2019, 11(12)

PubMed: 31769426 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(2):356-363

PubMed: 30446585 ( click the link to review the publication )

Cell Prolif, 2019, 52(5):e12638

PubMed: 31152465 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28205

PubMed: 30706473 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31850228 ( click the link to review the publication )

Front Oncol, 2019, 9:422

PubMed: 31192127 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31767884 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 381:114729

PubMed: 31445927 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.28410

PubMed: 30724378 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(3):559-565

PubMed: 30824188 ( click the link to review the publication )

Mol Med Rep, 2019, 20(1):33-40

PubMed: 31115502 ( click the link to review the publication )

Med Sci Monit, 2019, 25:7218-7227

PubMed: 31554782 ( click the link to review the publication )

Redox Biol, 2018, 16:47-58

PubMed: 29475134 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):747

PubMed: 29970878 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):911

PubMed: 30185800 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):739

PubMed: 29970892 ( click the link to review the publication )

Front Aging Neurosci, 2018, 10:378

PubMed: 30515090 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

J Cell Biochem, 2018, 119(12):9997-10004

PubMed: 30145830 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(11):1219-1229

PubMed: 30265530 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(8):748-756

PubMed: 29961813 ( click the link to review the publication )

BMC Neurosci, 2018, 19(1):52

PubMed: 30189852 ( click the link to review the publication )

Cell Biol Int, 2018, 42(8):959-964

PubMed: 29569784 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):447-454

PubMed: 29749519 ( click the link to review the publication )
Neoplasma, 2018, 65(5):701-707

PubMed: 29940761 ( click the link to review the publication )

Transl Cancer Res, 2018, 7(6):1548-1560

PubMed: 30761266 ( click the link to review the publication )

J Pharm Pharmacol, 2018, 70(2):259-267

PubMed: 29148068 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9425-9441

PubMed: 29507700 ( click the link to review the publication )

Oncotarget, 2018, 9(15):12261-12272

PubMed: 29552308 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(3):238-251

PubMed: 28218907 ( click the link to review the publication )

Nat Commun, 2017, 8:14091

PubMed: 28345588 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Sci Rep, 2017, 7:45136

PubMed: 28332584 ( click the link to review the publication )

Am J Pathol, 2017, 187(8):1736-1749

PubMed: 28627412 ( click the link to review the publication )

Mediators Inflamm, 2017, 2017:5706152

PubMed: 29056830 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0173473

PubMed: 28291820 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169585

PubMed: 28081222 ( click the link to review the publication )

Med Sci Monit, 2017, 23:5637-5649

PubMed: 29176544 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(9):1343-1349

PubMed: 28597147 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(9):9400-9408

PubMed: 31966812 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(2):2594-2603

PubMed: 27911877 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63911-63922

PubMed: 28969040 ( click the link to review the publication )

Sci Rep, 2017, 7:42062

PubMed: 28165023 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(4):1300-10

PubMed: 26927669 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(6):3130-3145

PubMed: 27980063 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2043

PubMed: 26775697 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(7):1504-14

PubMed: 27196761 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:305-313

PubMed: 27665476 ( click the link to review the publication )

Exp Cell Res, 2016, 340(1):81-90

PubMed: 26712518 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(1):54-60

PubMed: 27614310 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(4):1170-6

PubMed: 27073162 ( click the link to review the publication )

J Mol Neurosci, 2016, 59(4):567-78

PubMed: 27412469 ( click the link to review the publication )

Anticancer Res, 2016, 36(11):5849-5858

PubMed: 27793908 ( click the link to review the publication )

Oncotarget, 2016, 7(24):36971-36987

PubMed: 27175591 ( click the link to review the publication )

Oncotarget, 2016, 7(16):22687-99

PubMed: 27007150 ( click the link to review the publication )

NPJ Syst Biol Appl, 2016, 2:16027

PubMed: 28725479 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):1025-33

PubMed: 26269112 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.04.015

PubMed: 25934232 ( click the link to review the publication )

Sci Rep, 2015, 5:12059

PubMed: 26154270 ( click the link to review the publication )

Oncol Rep, 2015, 33(2):875-84

PubMed: 25484022 ( click the link to review the publication )

Mol Cell Biochem, 2015, 398(1-2):105-13

PubMed: 25223639 ( click the link to review the publication )

Growth Horm IGF Res, 2015, 25(3):115-20

PubMed: 25900365 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(30):29963-74

PubMed: 26298773 ( click the link to review the publication )

Oncoscience, 2015, 2(4):395-409

PubMed: 26097873 ( click the link to review the publication )

Oncoscience, 2015, 2(4):382-94

PubMed: 26097872 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(9):6597-610

PubMed: 25788264 ( click the link to review the publication )
Oncoscience, 2015,

PubMed: ( click the link to review the publication )

Oncoscience, 2015, 10.1155/2015/8332

PubMed: ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3244-2

PubMed: 25697899 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.184.

PubMed: 24998847 ( click the link to review the publication )

FASEB J, 2014, 27(7):2584-99

PubMed: 23507869 ( click the link to review the publication )

Cardiovasc Diabetol, 2014, 35(7):450-4

PubMed: 24836459 ( click the link to review the publication )

Carcinogenesis, 2014, 35(10):2232-43

PubMed: 24942865 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(9):1851-64

PubMed: 24769208 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Pediatr Res, 2014, 75(4):527-34

PubMed: 24366516 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:568693

PubMed: 25309914 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):362-7

PubMed: 25264192 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(1):72-8

PubMed: 25152399 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 450(1):646-51

PubMed: 24946212 ( click the link to review the publication )

Vet J, 2014, 201(1):83-90

PubMed: 24881508 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cell Logist, 2014, 4(1):e27732

PubMed: 24843827 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Rostock University, 2014, Lange F

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )
Cancer Lett, 2013, 336(2):319-24

PubMed: 23528835 ( click the link to review the publication )

Gynecol Oncol, 2013, 131(1):207-12

PubMed: 23877012 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1831(8):1322-34

PubMed: 23707264 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1828(5):1384-9

PubMed: 23376656 ( click the link to review the publication )

Sci Rep, 2013, 3:1697

PubMed: 23603888 ( click the link to review the publication )

J Biol Chem, 2013, 288(31):22836-48

PubMed: 23788636 ( click the link to review the publication )

Mol Pharmacol, 2013, 84(4):562-71

PubMed: 23877009 ( click the link to review the publication )

Biochimie, 2013, 101:50-9

PubMed: 24394624 ( click the link to review the publication )

Oncol Rep, 2013, 29(6):2422-30

PubMed: 23588929 ( click the link to review the publication )

Biochemistry, 2013, 53(3):462-72

PubMed: 24383815 ( click the link to review the publication )

Dig Dis Sci, 2013, 58(10):2873-80

PubMed: 23912246 ( click the link to review the publication )

PLoS One, 2013, 8(5):e61896

PubMed: 23658701 ( click the link to review the publication )

PLoS One, 2013, 8(8): e74420

PubMed: 24009772 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70804

PubMed: 23936469 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 443(2):447-52

PubMed: 24316214 ( click the link to review the publication )

Mol Biol Rep, 2013, 40(10):5645-55

PubMed: 24065522 ( click the link to review the publication )

Mol Med Rep, 2013, 7(2):642-8

PubMed: 23175237 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 66(3):737-46

PubMed: 23397419 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 65(2):217-27

PubMed: 23015227 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(10):2622-33

PubMed: 22461507 ( click the link to review the publication )

J Clin Endocrinol Metab, 2012, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(12):1898-912

PubMed: 23001822 ( click the link to review the publication )

J Biol Chem, 2012, 286(43):37389-98

PubMed: 21908616 ( click the link to review the publication )
Expert Opin Inv Drugs, 2012, 21(11):1597-606

PubMed: ( click the link to review the publication )

Mol Carcinog, 2012, 52(9):667-75

PubMed: 22488590 ( click the link to review the publication )

Surgery, 2012, 152(6):1218-24

PubMed: 23158188 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(11):1009-17

PubMed: 22825337 ( click the link to review the publication )

PLoS Biol, 2011, 9(9):e1001148

PubMed: 21931533 ( click the link to review the publication )

Cancer Lett, 2011, 310(1):118-28

PubMed: 21775054 ( click the link to review the publication )

J Pharmacol Exp Ther, 2011, 336(3):866-73

PubMed: 21148684 ( click the link to review the publication )

Radiat Oncol, 2011, 6:39

PubMed: 21496273 ( click the link to review the publication )

Cancer Res, 2010, 70(22):9106-17

PubMed: 21062988 ( click the link to review the publication )

Brit J Pharmacol, 2010, 160(2):355-66

PubMed: 20423345 ( click the link to review the publication )

Cytotechnology, 2010, 62(5):449-60

PubMed: 20842425 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Targets

Akt ^[1]
(MM.1S cells)

4.7 μM

In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. ^[1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. ^[2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. ^[3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HL-60	M2KwdWFxd3C2b4Ppd{BCe3O\|YYm=	MUmxNOKh\|ryP	MmHDNlQwPDhiaB?=	MmTxbY5lfWOnczDhdI9xfG:\|aYOgeIlu\S2mZYDlcoRmdnSueR?=	Mm\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzM{C5OlAoRjJyMUOwPVYxRC:jPh?=
MOLM	MYTBdI9xfG:\|aYOgRZN{e2G7	NEewO\|QyOMLizszN	M3XQNFI1NzR6IHi=	MUjpcoR2[2W\|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7	NYfnXoRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxN\|A6PjBpPkKwNVMxQTZyPD;hQi=>
OCI	NIH2UWVCeG:ydH;zbZMhSXO\|c3H5	M3\4SlExyqEQvF2=	M3i2VFI1NzR6IHi=	NFjpVYFqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MEm2NEc,OjBzM{C5OlA9N2F-
BJAB	MXrBdI9xfG:\|aYOgRZN{e2G7	MnvZNVDDqM7:TR?=	M1XrNFI1NzR6IHi=	MlLzbY5lfWOnczDhdI9xfG:\|aYOgeIlu\S2mZYDlcoRmdnSueR?=	NYHKPWhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxN\|A6PjBpPkKwNVMxQTZyPD;hQi=>
MAVER	NICxU\|JCeG:ydH;zbZMhSXO\|c3H5	NWf6c2FTOTEEoN88US=>	Mlj5NlQwPDhiaB?=	NUj2b403cW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=>	M3PJ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUOwPVYxLz5{MEGzNFk3ODxxYU6=
SKW6.4	MlH0RZBweHSxc3nzJGF{e3OjeR?=	NIrFVJUyOMLizszN	NHywfWszPC92ODDo	M3f1Solv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm=	NYqxSVJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxN\|A6PjBpPkKwNVMxQTZyPD;hQi=>
HL-60	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoP0Nk0yOMLizszN	NFLSZmI1QMLiaB?=	MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MlKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzM{C5OlAoRjJyMUOwPVYxRC:jPh?=
MOLM	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XxUlIuOTEEoN88US=>	NVj1[HBoPDkEoHi=	NU\0TWJmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M1z6UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUOwPVYxLz5{MEGzNFk3ODxxYU6=
OCI	NYjCZYgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnn5Nk0yOMLizszN	MoT3OFjDqGh?	Mn24bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NFLHVYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzNFk3OCd-MkCxN\|A6PjB:L3G+
BJAB	NH7yXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPjNk0yOMLizszN	MkDjOFjDqGh?	MmnwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MEm2NEc,OjBzM{C5OlA9N2F-
MAVER	NI\IZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDsNk0yOMLizszN	MUG0POKhcA>?	MYfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MEm2NEc,OjBzM{C5OlA9N2F-
SKW6.4	M3uwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPldlIzOi1zMNMg{txO	M4DWWVQ5yqCq	MlrnbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NX7m[XR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxN\|A6PjBpPkKwNVMxQTZyPD;hQi=>
A2780cis	M4LpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEP0Z\|MxNTJyIN88US=>	MYq0PE84OiCq	NFyxSmxKSzVywrC9xsA3yqEQvH2=	NU\XWpI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFUzQTZpPkKwOFA2Ojl4PD;hQi=>
A2780	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDaNE0zOCEQvF2=	M37XZ\|Q5Nzd{IHi=	MmfUTWM2OMLiPdMgN:Kh\|ryv	MonUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MEWyPVYoRjJyNEC1Nlk3RC:jPh?=
SKOV3	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoSxNE01OCEQvF2=	NXrPbFdpPzMEoHi=	MYPJR\|UxhjNyIN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NWXsZmJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFUzQTZpPkKwOFA2Ojl4PD;hQi=>
PA-1	NHLtNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzXUGUxNTRyIN88US=>	NVHzOoZUPzMEoHi=	M1rxcWlEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NWOyO5pCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFUzQTZpPkKwOFA2Ojl4PD;hQi=>
OAW-42	NIrJVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfVR2UxNTRyIN88US=>	NInr[Ys4OsLiaB?=	NIfyWIZKSzVyfkGwJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MnLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MEWyPVYoRjJyNEC1Nlk3RC:jPh?=
Bel-7402	MmDVRZBweHSxc3nzJGF{e3OjeR?=	NULZXopVPS9zMD:yNEDPxE1?	NIHkd4YzPC92ODDo	NHrySnlqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:\|dYLl	NUGxb2sxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4OFI1OjVpPkKwPFQzPDJ3PD;hQi=>
HepG2	M4TrZWFxd3C2b4Ppd{BCe3O\|YYm=	Mnf5OU8yOC9{MDFOwG0>	M4GzTFI1NzR6IHi=	MXnpcoR2[2W\|IHHwc5B1d3OrczDheEB1cGVibH;u[{11cW2nIHX4dI9{fXKn	NFH1NnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi0NlQzPSd-MkC4OFI1OjV:L3G+
Bel-7402	NWjMdmZETnWwY4Tpc44hSXO\|YYm=	NFPjXpA2NzFyL{KwJO69VQ>?	MV:yOEBp	NYfqcXJkemW\|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl	Mm\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6NEK0NlUoRjJyOESyOFI2RC:jPh?=
HepG2	NWrRO2dqTnWwY4Tpc44hSXO\|YYm=	MXy1M\|ExNzJyIN88US=>	Mk\yNlQhcA>?	MljtdoV{fWy2czDpckB1cGViYXPjeY12dGG2aX;uJI9nKGOnbHygcpVu[mW{IHnuJJRp\SCJMj;NJJBp[XOn	M4racVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOESyOFI2Lz5{MEi0NlQzPTxxYU6=
Bel-7402	NInsXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPoTII2NzFyL{KwM\|QxKM7:TR?=	NIfqVm8zPC92OD:3NkBp	NV72ZVBScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh2MkSyOUc,OjB6NEK0NlU9N2F-
HepG2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXy1M\|ExNzJyL{SwJO69VQ>?	MmP5NlQwPDhxN{KgbC=>	M{TTXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh2MkSyOUc,OjB6NEK0NlU9N2F-
CWR22RV1	MkW3SpVv[3Srb36gRZN{[Xl?	NUDpW\|FvPSEQvF2=	M1zTUVI1KGh?	M1P1N5Jm\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGFsfCC\|aXfubYZq[2GwdHz5	NGLQXGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS5OlI4Oyd-MkG0PVYzPzN:L3G+
CWR22RV1	NV3R[WxXSXCxcITvd4l{KEG\|c4PhfS=>	MlvmNVAh\|ryP	NXn1TpI3OjRiaB?=	MVzlcohidmOnczDyZYRq[XSrb36gbY5lfWOnZDDhdI9xfG:\|aYO=	MmHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2OU[yO\|MoRjJzNEm2Nlc{RC:jPh?=
CWR22RV1	MmSwR4VtdCCYaXHibYxqfHliQYPzZZk>	NFnaW\|EyOCEQvF2=	MoDwNlQhcA>?	MlzNbY5kemWjc3XzJJNmdnOrdHn2bZR6KG:oIHj1cYFvKEOZUkKyVnYyKGOnbHzzJJRwKHKjZHnheIlwdg>?	MnTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2OU[yO\|MoRjJzNEm2Nlc{RC:jPh?=
A498	NYGwNWF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEex[GcxNTJyIN88US=>	MnHKO\|IhcA>?	NX\Ec2ZHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NF\DU2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[0OFA2OCd-MkG2OFQxPTB:L3G+
769-P	MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVmwMVIxKM7:TR?=	NITkcFc4OiCq	MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NX\rZWltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OFQxPTBpPkKxOlQ1ODVyPD;hQi=>
CAKI-1	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXqwMVIxKM7:TR?=	M2W0eFczKGh?	NV7FWmcxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M2[1UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkS0NFUxLz5{MU[0OFA2ODxxYU6=
786-O	NXzH[XViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;RS\|AuOjBizszN	MoOyO\|IhcA>?	NGT4eGZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ2NEC1NEc,OjF4NESwOVA9N2F-
786-0	NUD4TGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWGwMVQxKM7:TR?=	MkSxO\|IhcA>?	NFnjXlBKSzVyfkWg{txO	NULsVWx[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OFQxPTBpPkKxOlQ1ODVyPD;hQi=>
769-P	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfPWnQxNTRyIN88US=>	MV23NkBp	M4LPUGlEPTC-NT2xNEDPxE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ2NEC1NEc,OjF4NESwOVA9N2F-
CAKI-1	NYDiXnJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvZNE01OCEQvF2=	MnzaO\|IhcA>?	M3XxN2lEPTC-MUCg{txO	NEfT[nQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[0OFA2OCd-MkG2OFQxPTB:L3G+
A498	NYnZdotmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1yyXFAuPDBizszN	MUS3NkBp	NFvQcnhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NEjFOlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[0OFA2OCd-MkG2OFQxPTB:L3G+
HT-29	NHvTfmVEgXSxdH;4bYNqfHliQYPzZZk>	NHLXXmw2KM7:TR?=	NF36WY81QCCq	MVflcohidmOnczDwZYNtcXSjeHXsJIlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg	NVLkZpNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|UxPTRpPkKxO\|c2ODV2PD;hQi=>
A2780	NYD3V2V4S3m2b4TvfIlkcXS7IFHzd4F6	M3HVbVUh\|ryP	MXq0PEBp	M3r3W4VvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>	M1HtPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{e1NFU1Lz5{MUe3OVA2PDxxYU6=
SKOV3	MUXDfZRwfG:6aXPpeJkhSXO\|YYm=	NHTQV5I2KM7:TR?=	MUC0PEBp	NYDEUpZk\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>?	M13PZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{e1NFU1Lz5{MUe3OVA2PDxxYU6=
CaOV3	NF7wZnNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3nYXFEwPS9zMDFOwG0>	Mn7ZOFghcA>?	MX;k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJiY3;0doVifGWmIIfpeIgheGGlbHn0ZZhmdA>?	M{DFSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{e1NFU1Lz5{MUe3OVA2PDxxYU6=
OCUT1	MYrGeY5kfGmxbjDBd5NigQ>?	NHi4eIQ{KM7:bR?=	M{DDeVI1KGh?	M2\QUINifXOnczDhJIRz[W2jdHnjJIlv[3KnYYPlJIlvKEd{L12gdIhie2V?	M33oW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEmwNlcyLz5{MkC5NFI4OTxxYU6=
K1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjGZ45FOC5zLUOg{txO	M2q3XFUh\A>?	MnPtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NVzRVW1JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwPVAzPzFpPkKyNFkxOjdzPD;hQi=>
OCUT1	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXHU5NvOC5zLUOg{txO	MUS1JIQ>	NYnuUVN3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NHrobZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5NFI4OSd-MkKwPVAzPzF:L3G+
K562	NX;3dJNCTnWwY4Tpc44hSXO\|YYm=	MVuyNEDPxE1?	MUi0PEBp	NHzHXI1qdmS3Y3XzJIF2fG:yaHHnfeKh	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRyN{KyPEc,OjJ2MEeyNlg9N2F-
HL-60	M130fGZ2dmO2aX;uJGF{e2G7	MnzTNk42NzVxMUCg{txO	NEPENGMzPCCq	NGrNbI5qdmS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSl7LNU8zKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRyN{KyPEc,OjJ2MEeyNlg9N2F-
Kasumi-1	Mn;VSpVv[3Srb36gRZN{[Xl?	MYqyMlUwPS9zMDFOwG0>	MnjUNlQhcA>?	NX;tSXhTcW6mdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFrOT\|EwOiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M3Hkd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEC3NlI5Lz5{MkSwO\|IzQDxxYU6=
HL-60	MV7GeY5kfGmxbjDBd5NigQ>?	NX;PZm1EOi53L{WvNVAh\|ryP	M4jXU\|I1KGh?	NFvrXodl\WO{ZXHz[ZMhSWu2IHHu[EBxNUGtdDDs[ZZmdHQEoHTvd4Uu\GWyZX7k[Y51dHl?	MmjEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2MEeyNlgoRjJ{NEC3NlI5RC:jPh?=
Kasumi-1	NFjue5dHfW6ldHnvckBCe3OjeR?=	MnO5Nk42NzVxMUCg{txO	M2TaO\|I1KGh?	MlXo[IVkemWjc3XzJGFsfCCjbnSgdE1Cc3RibHX2[Yx{yqCmb4PlMYRmeGWwZHXueIx6	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRyN{KyPEc,OjJ2MEeyNlg9N2F-
HL-60	MWnBdI9xfG:\|aYOgRZN{e2G7	MYWxNEDPxE1?	NEnKW24zPCCq	NHG1XotqdmS3Y3XzJIFxd3C2b4Ppdy=>	NF3UN5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSwO\|IzQCd-MkK0NFczOjh:L3G+
Kasumi-1	NIW2XnpCeG:ydH;zbZMhSXO\|c3H5	Mn3GNVAh\|ryP	MX[yOEBp	MmnCbY5lfWOnczDhdI9xfG:\|aYO=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRyN{KyPEc,OjJ2MEeyNlg9N2F-
HL-60	NIPNO41E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3j4elAuOjBizszN	MoTGNlQwPDhiaB?=	NVvSUY5k\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	NYm5Z21yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NFczOjhpPkKyOFA4OjJ6PD;hQi=>
Kasumi-1	M3Pyc2NmdGxiVnnhZoltcXS7IFHzd4F6	MXiwMVIxKM7:TR?=	NH\qfZIzPC92ODDo	MnPM[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	NVzzS5oyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NFczOjhpPkKyOFA4OjJ6PD;hQi=>
BON1	NF2zfFNHfW6ldHnvckBCe3OjeR?=	M3nRclcvPS9zMDFOwG0>	MXG4JIg>	M3:1ZoRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kB1cGViYX70bU1ieG:ydH;0bYMheHKxdHXpcpMhSkOOMjDhcoQhSmOuLWjM	NUH2PVRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVk1OzdpPkKyOFk6PDN5PD;hQi=>
BON1	MYfBdI9xfG:\|aYOgRZN{e2G7	M3v2dlAuOTBizszN	M{f4TVI1KGh?	NIPhOWNqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5	M2LUOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEm5OFM4Lz5{MkS5PVQ{PzxxYU6=
BON1	MlrzR4VtdCCYaXHibYxqfHliQYPzZZk>	NVL5dIh{OC1zMECg{txO	MnXINlQwPzJiaB?=	MoLT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	NXPBfVRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVk1OzdpPkKyOFk6PDN5PD;hQi=>
GOT1	MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M{fwNlAuOTByIN88US=>	M{XnXVI1Nzd{IHi=	NGTjVFVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	M{DDXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEm5OFM4Lz5{MkS5PVQ{PzxxYU6=
NCI-H727	MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MnrxNE0yODBizszN	MVKyOE84OiCq	NXjSc\|h4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz	NHvKXJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5PVQ{Pyd-MkK0PVk1Ozd:L3G+
MCAS	NE\FNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkXXTWM2OD1zMj61JO69VQ>?	NYnRTFVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|cxOTJpPkKzPFc4ODF{PD;hQi=>
A2780S	M2X5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1uxfGlEPTB;MUSuOUDPxE1?	NWDQdIZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|cxOTJpPkKzPFc4ODF{PD;hQi=>
OVCAR5	M1LQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MonRTWM2OD14Lkeg{txO	NGHZXok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|AyOid-MkO4O\|cxOTJ:L3G+
A2780CP	M2HCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFPHVGlKSzVyPUeuOkDPxE1?	MlKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{ewNVIoRjJ\|OEe3NFEzRC:jPh?=
HeyA8	NXPlOZhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX7MTXdFUUN3ME2yOE4{KM7:TR?=	NV;aPGVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|cxOTJpPkKzPFc4ODF{PD;hQi=>
OVCAR8	MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1zITWlEPTB;M{GuNUDPxE1?	M2nkZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEe3NFEzLz5{M{i3O\|AyOjxxYU6=
M41R	M33PVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M37pcmlEPTB;MUmuPEDPxE1?	NWHt[WdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|cxOTJpPkKzPFc4ODF{PD;hQi=>
M41	NH3zWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mk\PTWM2OD1{ND63JO69VQ>?	NV7WdG9IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|cxOTJpPkKzPFc4ODF{PD;hQi=>
TykNuR	NGjhZ\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYftS\|Y2UUN3ME21MlUh\|ryP	M{TZd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEe3NFEzLz5{M{i3O\|AyOjxxYU6=
TykNu	M3HxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWjO[G9FUUN3ME2zMlUh\|ryP	NH\5fGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|AyOid-MkO4O\|cxOTJ:L3G+
MGC803	MWDGeY5kfGmxbjDBd5NigQ>?	MXmwMlc2NzFywrFOwG0>	MXO0POKhcA>?	MnPX[IVkemWjc3XzJJAuSWu2IDjT[ZIhPDd\|KTygdE1IW0t\|zsKgLHNmeiB7KTygZY5lKENvTWnDJIxmfmWuc9Mg	NWnkcGtxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVIzPDZpPkKzPVEzOjR4PD;hQi=>
SGC7901	NVLmZnNuTnWwY4Tpc44hSXO\|YYm=	M4LMVlAvPzVxMUFCpO69VQ>?	M2XXSVQ5KGh?	NFTCb4ll\WO{ZXHz[ZMheC2Da4SgLHNmeiB2N{OpMEBxNUeVS{ROtkApW2W{IEmpMEBidmRiQz3NXWMhdGW4ZXzzxsA>	MnzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUKyOFYoRjJ\|OUGyNlQ3RC:jPh?=
U87MG	M1naSGNmdGxiVnnhZoltcXS7IFHzd4F6	NX34eItUOC1{NTFOwG0>	NVXW[JV6OjRvOU[gbC=>	MV\k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUWyNkc,OjRyNkW1NlI9N2F-
AsPC-1	M2jn[WZ2dmO2aX;uJGF{e2G7	NHjUO24xNjVizszN	M2jXbVI1KGh?	NIDBfZlqdmirYnn0d{BCc3RuIGO2T\|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB?	M4nuWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUG5O\|UyLz5{NEWxPVc2OTxxYU6=
MIA	MlvpSpVv[3Srb36gRZN{[Xl?	NYCyZlBlOC53IN88US=>	M3nWXVI1KGh?	MUjpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM\|IheGixc4Doc5J6dGG2aX;uxsA>	Mn3XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MUm3OVEoRjJ2NUG5O\|UyRC:jPh?=
PANC-1	MYfGeY5kfGmxbjDBd5NigQ>?	M16zW\|AvPSEQvF2=	M4X1fFI1KGh?	M3Sy[4lvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb\|EwOiCyaH;zdIhwenmuYYTpc47DqA>?	NWDUXWJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NVk4PTFpPkK0OVE6PzVzPD;hQi=>
AsPC-1	M2P1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWCwMVI2KM7:TR?=	NG\h[Wo4OiCq	MV;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NXHtd4h[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NVk4PTFpPkK0OVE6PzVzPD;hQi=>
MIA	NHfo[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXWwMVI2KM7:TR?=	M1;KNVczKGh?	M2\FdolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVzOUe1NUc,OjR3MUm3OVE9N2F-
PANC-1	NWP2fJJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[wPHpjOC1{NTFOwG0>	MYO3NkBp	MlnGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVzOUe1NUc,OjR3MUm3OVE9N2F-
Ema	NYfrcZROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3T1NVAvOeLCk{GwNQKBkc7:TR?=	MYi0PEBp	NXjMeVd1UUN3ME21PE44KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6MUWwPEc,OjR6OEG1NFg9N2F-
UL-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlP4NE4y6oDVMUCw5qCK\|ryP	NWDuOWZuPDhiaB?=	M3PES2lEPTB;Nz6wNUDPxE1?	M3zxVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEixOVA5Lz5{NEi4NVUxQDxxYU6=
CLBL-1	NWjPS5lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYmwMlHjiJNzMEFihKnPxE1?	NWPY[JVmPDhiaB?=	NXPSOJVlUUN3ME2zN{4xKM7:TR?=	NX;XXWk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2ODhpPkK0PFgyPTB6PD;hQi=>
GL-1	NVfZTWZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH63e48xNjIkgKOxNFDjiIoQvF2=	M3vsOFQ5KGh?	MnLqTWM2OD17LkmxJO69VQ>?	NXfFSppFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2ODhpPkK0PFgyPTB6PD;hQi=>
MDA-MB-231	NEToO2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvIfoNNOC1zMDFOwG0>	M1;OUVQ5KGh?	NWPqZ3lDTUN3ME2xMlE{6oDLwsJihKkxNjB5IN88US=>	NXvqOIVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVM2PzZpPkK1Nlk{PTd4PD;hQi=>
HCC1806	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmP1NE0yOCEQvF2=	MX[0PEBp	MkDzSWM2OD1{Lki05qCKyrIkgJmwMlA4KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7M{W3Okc,OjV{OUO1O\|Y9N2F-
RMG2	NVmzfJR[SXCxcITvd4l{KEG\|c4PhfS=>	MV:zNEDPxE1?	M37xSFI1KGh?	MUjpcoR2[2W\|IHHwc5B1d3Orcx?=	NHzMOIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWxPVE1QCd-MkW1NVkyPDh:L3G+
RMG1	NVPBbXlmSXCxcITvd4l{KEG\|c4PhfS=>	NWLie5ZwOzBizszN	M3rHcVI1KGh?	MoXobY5lfWOnczDhdI9xfG:\|aYO=	NUfJZo4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NVkyPDhpPkK1OVE6OTR6PD;hQi=>
A2780	NF20fpBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEG2fI8yNTNyIN88US=>	MonsOFghcA>?	NHvjWYVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NHy2bWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWxPVE1QCd-MkW1NVkyPDh:L3G+
SKOV3	MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NV7COm1KOS1\|MDFOwG0>	MX20PEBp	MkTj[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M{mxN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUG5NVQ5Lz5{NUWxPVE1QDxxYU6=
OVISE	M1e1[GNmdGxiVnnhZoltcXS7IFHzd4F6	NVHCOYF2OS1\|MDFOwG0>	NYPIW4pIPDhiaB?=	M1X4OYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	Mnv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MUmxOFgoRjJ3NUG5NVQ5RC:jPh?=
RMG2	MlftR4VtdCCYaXHibYxqfHliQYPzZZk>	M3jsXlEuOzBizszN	MV20PEBp	NUjLR2hs\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NViwToxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NVkyPDhpPkK1OVE6OTR6PD;hQi=>
HAC2	MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmjPNU0{OCEQvF2=	M1HqR\|czKGh?	NF7nbJdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M1\XflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUG5NVQ5Lz5{NUWxPVE1QDxxYU6=
KOC7C	NEi4NWRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXjKOW84OS1\|MDFOwG0>	NGHYVHY4OiCq	NXnheoY{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	Mmi5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MUmxOFgoRjJ3NUG5NVQ5RC:jPh?=
RMG2	NVnKOYVlS2WubDDWbYFjcWyrdImgRZN{[Xl?	NXLPcWdHOS1\|MDFOwG0>	NV;jOmdVPzJiaB?=	NV7KRnFH\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	Ml\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MUmxOFgoRjJ3NUG5NVQ5RC:jPh?=
RMG1	NXzFPYxDS2WubDDWbYFjcWyrdImgRZN{[Xl?	NHrENnIyNTNyIN88US=>	MlXVO\|IhcA>?	MUnk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NGnLUJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWxPVE1QCd-MkW1NVkyPDh:L3G+
H460	MnOzSpVv[3Srb36gRZN{[Xl?	NYTKbmttOyEQvF2=	Moj6PEBp	MlfmZoxw[2u\|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ7N{i5PUc,OjV4OUe4PVk9N2F-
A549	Mnf5SpVv[3Srb36gRZN{[Xl?	NIPVRZA{KM7:TR?=	NX7XeFRxQCCq	MX3icI9kc3NibWTPVmMyNCCjbnSgSXJMNU2DUFugZYN1cX[jdHnvckBkd22kaX7l[EB4cXSqIF3FT{0yPjJ?	M{j0[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm3PFk6Lz5{NU[5O\|g6QTxxYU6=
H460	MonMSpVv[3Srb36gRZN{[Xl?	NIjTW5Y{KM7:TR?=	NF\6VpY5KGh?	M{\DeIJtd2OtczDBT3Qh[WO2aY\heIlwdg>?	M1HYTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm3PFk6Lz5{NU[5O\|g6QTxxYU6=
A549	NX3OXppNTnWwY4Tpc44hSXO\|YYm=	MkDxN{DPxE1?	MYK4JIg>	M3fEd4Jtd2OtczDBT3Qh[WO2aY\heIlwdg>?	NH\xc4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5O\|g6QSd-MkW2PVc5QTl:L3G+
H460	Ml7jRZBweHSxc3nzJGF{e3OjeR?=	NXH6bFJkOS9\|IN88US=>	NXLTb4hUPDhiaB?=	MYrpcoR2[2W\|IHHwc5B1d3Orcx?=	NFG4bG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5O\|g6QSd-MkW2PVc5QTl:L3G+
A549	MXnBdI9xfG:\|aYOgRZN{e2G7	MnfGNU8{KM7:TR?=	M2n4XlQ5KGh?	NYnVTGtZcW6mdXPld{BieG:ydH;zbZM>	NU\JVHRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVc5QTlpPkK1Olk4QDl7PD;hQi=>
H460	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfmfZJpOC5\|LUGwJO69VQ>?	M3Xac\|I1Nzd{IHi=	M{\oeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MnTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUe4PVkoRjJ3Nkm3PFk6RC:jPh?=
A549	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHCdXQxNjNvMUCg{txO	MUSyOE84OiCq	M4jYd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M1njbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm3PFk6Lz5{NU[5O\|g6QTxxYU6=
U-87 MG	NVr2NZdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfMNlAwPDBizszN	NXL5bW5[OjRxNEigbC=>	MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MmjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7M{SyN\|IoRjJ3OUO0NlMzRC:jPh?=
HepG2	MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFH6TG8zOC92MDFOwG0>	MVGyOE81QCCq	NIHpb4dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MnLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7M{SyN\|IoRjJ3OUO0NlMzRC:jPh?=
U-87 MG	M1HHfmZ2dmO2aX;uJGF{e2G7	M4PrT\|IxyqEQvF2=	NEXyPIM3NzJ2IHi=	M2fqWolv[3KnYYPld{B1cGViYYX0c5Bp[WerYzDmcJV5KCCjdDC2JIghf2irbHWgbY5pcWKrdIOgeIhqeyCobIX4JIF1KDJ2aB?=	M1XRbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO0NlMzLz5{NUmzOFI{OjxxYU6=
HepG2	MYLGeY5kfGmxbjDBd5NigQ>?	MXqyNOKh\|ryP	M{L3UlYwOjRiaB?=	MUDk[YNz\WG\|ZYOgUGM{NUmLIHTl[5Ji\GG2aX;uxsBnem:vIE[gbC=>	NVj5Vlk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|QzOzJpPkK1PVM1OjN{PD;hQi=>
U-87 MG	Mo\kSpVv[3Srb36gRZN{[Xl?	MlX4NlDDqM7:TR?=	NHfId4o3NzJ2IHi=	NXvOXndocW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gUGM{NUmLIHPveJJm[XSnZDD3bZRpKEOT	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl\|NEKzNkc,OjV7M{SyN\|I9N2F-
HepG2	MnfQSpVv[3Srb36gRZN{[Xl?	NEPMWIkzOMLizszN	MVi2M\|I1KGh?	MWHpcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iCOQ{OtTWkh[2:2cnXheIVlKHerdHigR3E>	NGPud2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmzOFI{Oid-MkW5N\|QzOzJ:L3G+
U-87 MG	MVXGeY5kfGmxbjDBd5NigQ>?	NYTrPG4zOjEEoN88US=>	M1H1clI1yqCq	MWXpcoNz\WG\|ZYOg[I92[mynLX3lcYJz[W6nIHLveY5lKHO2coXjeJVz\XN?	NEDzOZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmzOFI{Oid-MkW5N\|QzOzJ:L3G+
HepG2	M13uTGZ2dmO2aX;uJGF{e2G7	NWjHbW13OjEEoN88US=>	MlT2NlTDqGh?	MYfwdo9lfWOnczDhckBqdnSnboPlJIN6fG:ybHHzcYlkKH[jY4XvcIl7[XSrb36gZ49zemW\|cH;u[Ilv\yC2bzDhJI5wfGGkbHWg[Ilt[XSjdHnvckBw\iC2aHWgSXIh[2m\|dHXycpM>	NI\CWG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmzOFI{Oid-MkW5N\|QzOzJ:L3G+
T24 BC	M3zsXmFxd3C2b4Ppd{BCe3O\|YYm=	NULNSXZiOi53IN88US=>	NH65UGMzPCCq	MX3z[Y5{cXSrenXzJGJEKGOnbHzzJJRwKHOxcnHm[Y5q[i2rbnT1Z4VlKGGyb4D0c5Rq[8Li	NX;WPHZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzNpPkK2NFk4QDd\|PD;hQi=>
T24 BC	M3:wfGNmdGxiVnnhZoltcXS7IFHzd4F6	MmXtNE42NzFxMj61JO69VQ>?	MofMNlQhcA>?	M{XNSYVvcGGwY3XzJJNwemGoZX7pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHTlZ5Jm[XOn	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB7N{i3N{c,OjZyOUe4O\|M9N2F-
T24 BC	M1nvc2Z2dmO2aX;uJGF{e2G7	M2jMbFAvPS9zL{KuOUDPxE1?	NFy3bmk{KGh?	NWPSSGtkemWmdXPld{B1cGViYnHzZYwhS0JidInyc5NqdmVicHjvd5Bpd3K7bHH0bY9vKGyndnXsd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MkL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOUe4O\|MoRjJ4MEm3PFc{RC:jPh?=
RBL2H3	M13R[mZ2dmO2aX;uJIF{e2G7			NVvETo9mXG:6aXPpeJkhcW5icnH0JHJDVDKKMzDj[YxteyxiTWTEQVI2\|ryP	NGX1dGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1N\|U3PSd-MkCxOVM2PjV:L3G+
PC3	M{TlZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MkHNS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGdKPTB;MD60OO69VQ>?	MnnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NEOxOFEoRjJzNUSzNVQyRC:jPh?=
NUGC3	MnLqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			Mn\ES5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUnVISzNiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlU1\|ryP	NG\uSng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW0N\|E1OSd-MkG1OFMyPDF:L3G+
HCT15	MlPrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NFLLPXRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1RzNTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVEvOjYQvF2=	Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NEOxOFEoRjJzNUSzNVQyRC:jPh?=
MDA-MB-231	M4O1VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NHHWNJJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGdKPTB;Mj64Ou69VQ>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV2M{G0NUc,OjF3NEOxOFE9N2F-
NCI-H23	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M2jNeGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkOgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NF01NjJzzszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV2M{G0NUc,OjF3NEOxOFE9N2F-
ACHN	MkTLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MUHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBR2hPKGOnbHzzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGdKPTB;ND61Ou69VQ>?	MlHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NEOxOFEoRjJzNUSzNVQyRC:jPh?=
A549	NILObm5HfW6ldHnvckBie3OjeR?=		MUezNEBucW6\|	MlOwTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIlve3WuaX6td5RqdXWuYYTl[EBpfW2jbjDBOVQ6KGOnbHzzJJRz\WG2ZXSgNkBpenNiYnXmc5JmKGmwc4XsbY4he3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCHTFnTRUwhUUN3ME21MlPPxE1?	NID2cnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGzPFMxQSd-MkKxN\|g{ODl:L3G+
A549	MoXjR5l1d3SxeHnjbZR6KGG\|c3H5		NWLMdmxuOjRiaILz	MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCLQ{WwQVfPxE1?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF\|OEOwPUc,OjJzM{izNFk9N2F-
KATO III	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		NF3rUm0zPCCqcoO=	MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRXRQKEmLSTDj[YxteyCjZoTldkAzPCCqcoOgZpkhTkGFUzDhcoFtgXOrczygTWM2OD1zMj64{txO	NVnFfllXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxN\|g{ODlpPkKyNVM5OzB7PD;hQi=>
MCF7	MlLTR5l1d3SxeHnjbZR6KGG\|c3H5		Ml3oNlQhcHK\|	M4r6UGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JGZCS1NiYX7hcJl{cXNuIFnDOVA:OTNwM988US=>	NY\GW5A{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxN\|g{ODlpPkKyNVM5OzB7PD;hQi=>
PC3	NHHmNlJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NUHFNZZwT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkS0{txO	NFzJV4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2OlE5OSd-MkOyOlYyQDF:L3G+
NUGC3	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M1jYbWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5WT0N\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkW0{txO	NIfBXZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2OlE5OSd-MkOyOlYyQDF:L3G+
HCT15	NYS5e2F5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M1j4bGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDF3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1zLkK1{txO	NHzo[m49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2OlE5OSd-MkOyOlYyQDF:L3G+
MDA-MB-231	Ml7mS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M171WWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVIvQDcQvF2=	M2X4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Mk[2NVgyLz5{M{K2OlE5OTxxYU6=
NCI-H23	NFrMdVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M1qycmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkOgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUSuNlHPxE1?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4NkG4NUc,OjN{Nk[xPFE9N2F-
ACHN	MoDhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NFHoeFZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCS0iQIHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD12LkW2{txO	NHLiTFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2OlE5OSd-MkOyOlYyQDF:L3G+
A549	NVfGVVkzTnWwY4Tpc44h[XO\|YYm=		MlW5NkBpenN?	MoXWTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIHnud5VtcW5vc4TpcZVt[XSnZDDBOVQ6KGOnbHzzJIlv[3WkYYTl[EBnd3JiMjDodpMheHKrb4KgeI8hcW6\|dXzpck1qdmS3Y4Tpc44hdWWjc4Xy[YQh[W[2ZYKgN\|AhdWmwczDifUBGVEmVQTygTWM2OD13LkROwG0>	NG\VXYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxOVA5Oyd-MkO0NVUxQDN:L3G+
A549	Mlz0R5l1d3SxeHnjbZR6KGG\|c3H5			NFH1OoREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF04\|ryP	NHfWOWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxOVA5Oyd-MkO0NVUxQDN:L3G+
KATO III	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=			Mk\BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2FVVyCLSVmgZ4VtdHNiYomg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxRTF{LklOwG0>	MmXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUWwPFMoRjJ\|NEG1NFg{RC:jPh?=
MCF7	NHyxXZBEgXSxdH;4bYNqfHliYYPzZZk>			NHzKSlhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0yOy5\|zszN	NGnwVnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxOVA5Oyd-MkO0NVUxQDN:L3G+
PC3	NH\4PFhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MlHGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUCuOFTPxE1?	MoXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Nke5OVAoRjJ\|NU[3PVUxRC:jPh?=
NUGC3	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6XR1OzJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlU1\|ryP	NIXJXok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2O\|k2OCd-MkO1Olc6PTB:L3G+
HCT15	MVHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			Mo\uRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxOUBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9NU4zPc7:TR?=	NUXqVY8zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1Olc6PTBpPkKzOVY4QTVyPD;hQi=>
MDA-MB-231	NXvFc2NbSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			Mm\ERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1{Lki2{txO	MkHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Nke5OVAoRjJ\|NU[3PVUxRC:jPh?=
NCI-H23	NUHMXYx5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			MkW4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFI{KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF01NjJzzszN	NEPFT449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2O\|k2OCd-MkO1Olc6PTB:L3G+
ACHN	NVztdnpqSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M3XiVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQVPIUkBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9OE42Ps7:TR?=	Mm\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Nke5OVAoRjJ\|NU[3PVUxRC:jPh?=
PC3	NX;FVXpYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4PHZ\|Q5KGi{cx?=	Ml6xS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTB;MD60OO69VQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NUe1PUc,OjRyOUW3OVk9N2F-
NUGC3	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M37zVlQ5KGi{cx?=	MmX3S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUnVISzNiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlU1\|ryP	MoTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUW3OVkoRjJ2MEm1O\|U6RC:jPh?=
HCT15	NH;0TZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mny5OFghcHK\|	NVHrc2RiT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUWgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0yNjJ3zszN	NFzu[Gg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVc2QSd-MkSwPVU4PTl:L3G+
MDA-MB-231	NHPiZndIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MU[0PEBpenN?	M17Odmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1{Lki2{txO	NX:0fZB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVU4PTlpPkK0NFk2PzV7PD;hQi=>
NCI-H23	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWS0PEBpenN?	NYmydIR4T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN{Bk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTRwMkJOwG0>	MorrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUW3OVkoRjJ2MEm1O\|U6RC:jPh?=
ACHN	NVTvUGpQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXfJZWhXPDhiaILz	NIPrfoRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCS0iQIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9OE42Ps7:TR?=	NXvpcZd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVU4PTlpPkK0NFk2PzV7PD;hQi=>
A549	NUHXd4NvS3m2b4TvfIlkcXS7IHHzd4F6		NFPkTXozPCC2bzC3NkBpenN?	NG\HZmdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFI1KHSxIEeyJIhzeyCkeTDoZYVud2O7dH;t[ZRzgSxiSVO1NF01NjF5zszN	M3rVTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlIxLz5{NEmwNFYzODxxYU6=
Rosetta cells	MUfGeY5kfGmxbjDhd5NigQ>?			MX3Jcohq[mm2aX;uJI9nKHerbHSteJlx\SCqdX3hckBROzijbIDoZUBOSVCNIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJHJwe2W2dHGgZ4VtdHNuIFnDOVA:OS5{zszN	NVTPUnlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GyO\|Q{OTZpPkOxNlc1OzF4PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-PDK1 / p-GSK3α/β / p-S6R ; PubMed: 17761832 Blood BCWM.1 cells were cultured with perifosine for 6 hours with doses that ranged from 2 to 20 μM. Whole cell lysates were subjecting to Western blotting using anti–p-Akt ser473, -Akt, –p-PDK1, –p-GSK3α/β, –p-S6R, and α-tubulin antibodies. p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1; PubMed: 19920197 Cancer Res The indicated cell lines were treated with the given concentrations of perifosine (PRFS) for 8 h. PARP; PubMed: 25519148 Mol Cancer Res Perifosine induces apoptosis. RMG1 and RMG2 cells were treated with or without 30 μM perifosine for 24 h. Cells were harvested, and the effect of perifosine was evaluated by western blotting p-AKT / AKT / p-S6K1 / S6K1 ; PubMed: 25519148 Mol Cancer Res The effect of perifosine on AKT-mTOR activation in vitro. RMG1 and RMG2 cells were treated with 0, 3, 10, 30 or 50 μM perifosine for 6 h in the presence of 10% FBS. Cells were harvested, and equivalent amounts (30 μg) of protein were subjected to SDS-PAGE and blotted with anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-S6K1 (Thr389), anti-S6K1, or anti-β-actin antibodies.	17761832 19920197 25519148
Growth inhibition assay	Cell viability; PubMed: 28332584 Sci Rep Cell survival measured by MTT assay and IC50 of perifosine in a panel of eleven human cancer cells.	28332584

In vivo

Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. ^[2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. ^[3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. ^[5]

Protocol

Kinase Assay:^[3]	- Collapse Akt kinase assay: MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:^[2]	- Collapse Cell lines: Human glioma cell lines Concentrations: 0, 15, 30 and 45 μM Incubation Time: 48 hours Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader. (Only for Reference)
Animal Research:^[3]	- Collapse Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old). Dosages: 250 mg/kg/wk or 36 mg/kg/d Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	8 mg/mL (17.32 mM)
	DMSO	Insoluble
	Ethanol	'15 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Perifosine (KRX-0401) SDF

Molecular Weight	461.66
Formula	C₂₅H₅₂NO₄P
CAS No.	157716-52-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NSC639966, D21266
Smiles	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01224730	Completed	Drug: perifosine	Cancer	AEterna Zentaris	January 24 2012	Phase 1
NCT01049841	Completed	Drug: perifosine + temsirolimus	Pediatric Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|NATL COMP CA NETWORK\|Pfizer\|AEterna Zentaris	January 2010	Phase 1
NCT01048580	Completed	Drug: Perifosine\|Drug: Capecitabine	Colon Cancer	AEterna Zentaris\|SCRI Development Innovations LLC	October 2009	Phase 1
NCT00776867	Completed	Drug: perifosine	Solid Tumors	Memorial Sloan Kettering Cancer Center\|University of Wisconsin Madison\|Duke University\|AEterna Zentaris	October 2008	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Selective Akt Inhibitor

CCT128930 : AKT2-selective, IC50=6 nM.
Most Potent Akt Inhibitor

AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.
Akt Inhibitor in Clinical Trial

Ipatasertib (GDC-0068) : Phase II for Prostate Cancer and Gastric Cancer.
Newest Akt Inhibitor

AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

Afuresertib (GSK2110183) ^New

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
AT13148 ^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79 ^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
Capivasertib (AZD5363)

Capivasertib (AZD5363) potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068, RG7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.
Triciribine (NSC 154020)

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol (NSC 293100)

Honokiol (NSC 293100) is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Perifosine (KRX-0401)